CILOXAN Drug Patent Profile
✉ Email this page to a colleague
When do Ciloxan patents expire, and what generic alternatives are available?
Ciloxan is a drug marketed by Novartis and is included in two NDAs.
The generic ingredient in CILOXAN is ciprofloxacin hydrochloride. There are thirty-four drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ciloxan
A generic version of CILOXAN was approved as ciprofloxacin hydrochloride by PAI HOLDINGS PHARM on June 9th, 2004.
Summary for CILOXAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 10 |
| Raw Ingredient (Bulk) Api Vendors: | 92 |
| Clinical Trials: | 6 |
| Patent Applications: | 3,288 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CILOXAN |
| What excipients (inactive ingredients) are in CILOXAN? | CILOXAN excipients list |
| DailyMed Link: | CILOXAN at DailyMed |
Recent Clinical Trials for CILOXAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National University of Malaysia | Phase 1/Phase 2 |
| Santen Pharmaceutical Co., Ltd. | Phase 1/Phase 2 |
| CR-CSSS Champlain-Charles-Le Moyne | Phase 3 |
Pharmacology for CILOXAN
| Drug Class | Quinolone Antimicrobial Fluoroquinolone Antibacterial |
| Mechanism of Action | Cytochrome P450 1A2 Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for CILOXAN
US Patents and Regulatory Information for CILOXAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | CILOXAN | ciprofloxacin hydrochloride | OINTMENT;OPHTHALMIC | 020369-001 | Mar 30, 1998 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Novartis | CILOXAN | ciprofloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019992-001 | Dec 31, 1990 | AT | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CILOXAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | CILOXAN | ciprofloxacin hydrochloride | OINTMENT;OPHTHALMIC | 020369-001 | Mar 30, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
| Novartis | CILOXAN | ciprofloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019992-001 | Dec 31, 1990 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CILOXAN
See the table below for patents covering CILOXAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | S62161728 | ANTIBACTERIAL | ⤷ Try a Trial |
| Singapore | 44685 | ⤷ Try a Trial | |
| Japan | H04253963 | 1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO- 4-OXO-7-PIPERAZINOQUINOLINE- 3-CARBOXYLIC ACID | ⤷ Try a Trial |
| Denmark | 161460 | ⤷ Try a Trial | |
| Ireland | 812032 | ⤷ Try a Trial | |
| Norway | 822346 | ⤷ Try a Trial | |
| Ireland | 51541 | 7-AMINO-1-CYCLOPROPYL-4-OXO-1,4-DIHYDRO-NAPHTHYRIDINE-3-CARBOXYLIC ACIDS,PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CILOXAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1429780 | 132013902137451 | Italy | ⤷ Try a Trial | PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106 |
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 1429780 | 13C0012 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808 |
| 1429780 | 122012000070 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
